FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2189196502> ?p ?o ?g. }

• W2189196502 endingPage "A458" @default.
• W2189196502 startingPage "A458" @default.
• W2189196502 abstract "This study aims to evaluate cost effectiveness of currently available first-line TKIs, Dasatinib (100mg), Nilotinib (600 mg) and Imatinib (400mg), in treatment of newly diagnosed CML patients in Korea. We developed a Markov model model composed of four health states: response in chronic-phase (CP), no-response in CP, accelerated or blastic phase (AP/BP) and Death. Progression rate to AP/BP is assumed to be dependent on the presence of cytogenetic or molecular response to TKI at 12 month. Clinical effectiveness were obtained from DASISION and ENESTnd trials. In terms of cost, only direct medical costs (e.g. outpatient, hospitalisation and medication costs) with 5% of patient copayment were included into the study. Average medical cost of CML patients were calculated using claims data from the National Health Insurance Service of Korea. All costs were measured in Korean won (KRW) and converted to US dollars (USD) using 2014 official exchange rate (1USD=1,053.22KRW). Discount rate of 5% was applied to cost and effectiveness. Based on complete cytogenetic response rates at 12 month, Imatinib ($277,971) was less costly than Dasatinib ($388,232) and Nilotinib ($445,548). Life-year gains of Dasatinib (15.18 LYs), were superior to other TKIs (Imatinib: 14.52 LYs, Nilotinib: 15.13 LYs), but ICER was $167,010 per LYs which far exceeds current willingness to pay level ($28,484) in Korea. Applying major molecular response rates at 12 month, the most effective strategy was Nilotinib ($416,513, 14.76 LYs), but its cost was the highest among others: Dasatinib ($365,602, 14.47 LYs) and Imatinib ($300,490, 13.8 LYs). The ICER of Dasatinib and Nilotinib was $98,483 and $170,431 per LYs respectively compared to Imatinib. Given the current willingness to pay level of $28,959 in Korean setting, Imatinib (400 mg) was found out to be the most cost-effective strategy compared to Dasatinib (100mg) and Nilotinib (300 mg)." @default.
• W2189196502 created "2016-06-24" @default.
• W2189196502 creator A5053757960 @default.
• W2189196502 creator A5054208609 @default.
• W2189196502 creator A5054354119 @default.
• W2189196502 creator A5065276262 @default.
• W2189196502 creator A5070489074 @default.
• W2189196502 creator A5086603522 @default.
• W2189196502 date "2015-11-01" @default.
• W2189196502 modified "2023-09-26" @default.
• W2189196502 title "Cost-Effectiveness Of First-Line Tyrosine Kinase Inhibitors (Tkis) In Newly Diagnosed Chronic Myeloid Leukemia (Cml) Patients In Korea: Comparison Of Dasatinib (100mg), Nilotinib (600mg) And Imatinib (400mg)" @default.
• W2189196502 doi "https://doi.org/10.1016/j.jval.2015.09.1177" @default.
• W2189196502 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26532577" @default.
• W2189196502 hasPublicationYear "2015" @default.
• W2189196502 type Work @default.
• W2189196502 sameAs 2189196502 @default.
• W2189196502 citedByCount "2" @default.
• W2189196502 countsByYear W21891965022017 @default.
• W2189196502 crossrefType "journal-article" @default.
• W2189196502 hasAuthorship W2189196502A5053757960 @default.
• W2189196502 hasAuthorship W2189196502A5054208609 @default.
• W2189196502 hasAuthorship W2189196502A5054354119 @default.
• W2189196502 hasAuthorship W2189196502A5065276262 @default.
• W2189196502 hasAuthorship W2189196502A5070489074 @default.
• W2189196502 hasAuthorship W2189196502A5086603522 @default.
• W2189196502 hasBestOaLocation W21891965021 @default.
• W2189196502 hasConcept C121608353 @default.
• W2189196502 hasConcept C126322002 @default.
• W2189196502 hasConcept C143998085 @default.
• W2189196502 hasConcept C170493617 @default.
• W2189196502 hasConcept C2777413986 @default.
• W2189196502 hasConcept C2777583451 @default.
• W2189196502 hasConcept C2778729363 @default.
• W2189196502 hasConcept C2778820342 @default.
• W2189196502 hasConcept C2779536868 @default.
• W2189196502 hasConcept C42362537 @default.
• W2189196502 hasConcept C71924100 @default.
• W2189196502 hasConceptScore W2189196502C121608353 @default.
• W2189196502 hasConceptScore W2189196502C126322002 @default.
• W2189196502 hasConceptScore W2189196502C143998085 @default.
• W2189196502 hasConceptScore W2189196502C170493617 @default.
• W2189196502 hasConceptScore W2189196502C2777413986 @default.
• W2189196502 hasConceptScore W2189196502C2777583451 @default.
• W2189196502 hasConceptScore W2189196502C2778729363 @default.
• W2189196502 hasConceptScore W2189196502C2778820342 @default.
• W2189196502 hasConceptScore W2189196502C2779536868 @default.
• W2189196502 hasConceptScore W2189196502C42362537 @default.
• W2189196502 hasConceptScore W2189196502C71924100 @default.
• W2189196502 hasIssue "7" @default.
• W2189196502 hasLocation W21891965021 @default.
• W2189196502 hasOpenAccess W2189196502 @default.
• W2189196502 hasPrimaryLocation W21891965021 @default.
• W2189196502 hasRelatedWork W114456681 @default.
• W2189196502 hasRelatedWork W1988974635 @default.
• W2189196502 hasRelatedWork W2086747176 @default.
• W2189196502 hasRelatedWork W2163329109 @default.
• W2189196502 hasRelatedWork W2184746615 @default.
• W2189196502 hasRelatedWork W2189196502 @default.
• W2189196502 hasRelatedWork W2266796555 @default.
• W2189196502 hasRelatedWork W2321213113 @default.
• W2189196502 hasRelatedWork W2884382178 @default.
• W2189196502 hasRelatedWork W4230849756 @default.
• W2189196502 hasVolume "18" @default.
• W2189196502 isParatext "false" @default.
• W2189196502 isRetracted "false" @default.
• W2189196502 magId "2189196502" @default.
• W2189196502 workType "article" @default.